Sarah Leary, MD
Sarah Leary, MD, MS, is the Medical Director of the Pediatric Brain Tumor Program and the Medical Director of Clinical Research in the Cancer and Blood Disorders Center at Seattle Children’s Hospital. She is an Associate Professor of Pediatrics at the University of Washington School of Medicine a
Seattle Children’s Hospital is home to the largest pediatric brain tumor program in the Northwestern United States. With an international reputation for comprehensive care of pediatric brain tumors, Seattle Children’s Brain Tumor Program treats central nervous system (CNS) tumors in children, adolescents and young adults. For more than a decade, their Cancer and Blood Disorders Center has consistently ranked among the top pediatric oncology programs in the country by U.S. News & World Report. Seattle Children’s has ranked as one of the nation’s best children’s hospitals for more than 25 years.
At Seattle Children’s, children receive the most advanced care, including access to advanced neurosurgery, proton radiation therapy and clinical trials offering promising new treatments.
Young patients have the opportunity to take part in research as part of their medical treatment. Seattle Children’s doctors and researchers are leaders in developing studies of new drugs and other new treatments, including Dr. Sarah Leary, who is the director of their Brain Tumor Program, the vice-chair of the Children’s Oncology Group (COG) CNS committee, and the principal investigator of research on tumor paint.
Seattle Children’s is also an international leader in immunotherapy. Dr. Nicholas Vitanza's phase 1 chimeric antigen receptor (CAR) T cell trials, called BrainChild-01, -02, and -03, use a patient’s engineered T cells to target CNS tumors in children and young adults with recurrent/refractory central nervous system tumors or with diffuse intrinsic pontine glioma (DIPG) or diffuse midline glioma, H3 K27M-mutant (DMG).
Jeffrey Stevens | Clinical Research Coordinatorhttp://www.seattlechildrens.org
James M. Olson, MD, PhD
James M. Olson, MD, PhD, is attending physician at Seattle Childrens Hospital and member of Fred Hutchinson Cancer Research Center (FHCRC); he is professor of Pediatric Hematology-Oncology and adjunct professor of Pathology at the University of Washington School of Medicine and on the faculty in
Nicholas Alexander Vitanza, MD
I first became interested in pediatric oncology because it combined both of his passions: working with critically ill children and participating in basic science research. During my pediatric hematology/oncology fellowship at NYU I gained exposure to pediatric neuro-oncology, in which patients ar
Jeffrey Stevens, BS
I have a background working as the Lead Lab Technician in a cancer lab for over 10 years, and transitioned to working with the CBTN in April of 2014. As the Lead Clinical Research Coordinator at Seattle Children’s for our biology, banking, and precision medicine studies, I manage one of the large